364 related articles for article (PubMed ID: 12236850)
1. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential.
Furuta S; Akagawa N; Kamada E; Hiyama A; Kawabata Y; Kowata N; Inaba A; Matthews A; Hall M; Kurimoto T
Br J Clin Pharmacol; 2002 Sep; 54(3):295-303. PubMed ID: 12236850
[TBL] [Abstract][Full Text] [Related]
2. Traditional Herbal Formulas to as Treatments for Musculoskeletal Disorders: Their Inhibitory Effects on the Activities of Human Microsomal Cytochrome P450s and UDP-glucuronosyltransferases.
Jin SE; Seo CS; Shin HK; Ha H
Pharmacogn Mag; 2016; 12(48):241-252. PubMed ID: 27867264
[TBL] [Abstract][Full Text] [Related]
3. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.
Prakash C; Kamel A; Cui D; Whalen RD; Miceli JJ; Tweedie D
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):35S-42S. PubMed ID: 10771452
[TBL] [Abstract][Full Text] [Related]
4. Effects of Radix Astragali and Radix Rehmanniae, the components of an anti-diabetic foot ulcer herbal formula, on metabolism of model CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 probe substrates in pooled human liver microsomes and specific CYP isoforms.
Or PM; Lam FF; Kwan YW; Cho CH; Lau CP; Yu H; Lin G; Lau CB; Fung KP; Leung PC; Yeung JH
Phytomedicine; 2012 Apr; 19(6):535-44. PubMed ID: 22261394
[TBL] [Abstract][Full Text] [Related]
5. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
[TBL] [Abstract][Full Text] [Related]
6. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
7. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
8. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.
Sandberg M; Yasar U; Strömberg P; Höög JO; Eliasson E
Br J Clin Pharmacol; 2002 Oct; 54(4):423-9. PubMed ID: 12392591
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
10. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
11. Metabolic interactions of rosmarinic acid with human cytochrome P450 monooxygenases and uridine diphosphate glucuronosyltransferases.
Kim SB; Kim KS; Kim DD; Yoon IS
Biomed Pharmacother; 2019 Feb; 110():111-117. PubMed ID: 30466000
[TBL] [Abstract][Full Text] [Related]
12. In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates.
Zhao K; Ding M; Cao H; Cao ZX
J Pharm Pharmacol; 2012 Oct; 64(10):1445-51. PubMed ID: 22943175
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4.
Renwick AB; Lewis DF; Fulford S; Surry D; Williams B; Worboys PD; Cai X; Wang RW; Price RJ; Lake BG; Evans DC
Xenobiotica; 2001 Apr; 31(4):187-204. PubMed ID: 11465405
[TBL] [Abstract][Full Text] [Related]
14. Ethanol oxidation into acetaldehyde by 16 recombinant human cytochrome P450 isoforms: role of CYP2C isoforms in human liver microsomes.
Hamitouche S; Poupon J; Dreano Y; Amet Y; Lucas D
Toxicol Lett; 2006 Dec; 167(3):221-30. PubMed ID: 17084997
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of a novel phosphodiesterase-IV inhibitor (V11294) by human hepatic cytochrome P450 forms.
Subrahmanyam V; Renwick AB; Walters DG; Price RJ; Tonelli AP; Lake BG
Xenobiotica; 2002 Jun; 32(6):521-34. PubMed ID: 12160484
[TBL] [Abstract][Full Text] [Related]
16. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
[TBL] [Abstract][Full Text] [Related]
17. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
18. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
19. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
